Title: Regis Gayon: Innovator in Retroviral Systems
Introduction
Regis Gayon is a notable inventor based in France, recognized for his contributions to the field of retroviral systems. His work primarily focuses on the transfer of non-viral RNA into target cells, showcasing innovative approaches to gene delivery.
Latest Patents
Regis Gayon holds two significant patents. The first patent, titled "Particule Retrovirale Comportant Au Moins Deux Arn Non Viraux Encapsides," relates to a retroviral system designed for the transfer of non-viral RNA into target cells. This invention involves retroviral particles that can deliver multiple RNAs, incorporating a protein derived from the Gag polyprotein and an envelope protein, along with at least two encapsidated non-viral RNAs. Each RNA sequence of interest is linked to an encapsidation sequence recognized by a binding domain introduced into the Gag protein or integrase.
The second patent, "Method For Detecting Or Measuring The Impact Of A Viral Vector Composition On Eukaryotic Cells And Biomarkers Used Thereof," outlines methods and compositions for characterizing cellular changes in response to viral vector compositions. This method assesses the quality of a viral vector composition for transgene transfer by measuring the expression levels of specific biomarkers.
Career Highlights
Regis Gayon has made significant strides in the field of biotechnology, particularly in developing innovative methods for gene delivery. His expertise in retroviral systems has positioned him as a key figure in advancing research in this area.
Collaborations
Throughout his career, Regis has collaborated with esteemed colleagues, including Pascale Bouille and Helene Vergnault. These partnerships have contributed to the development of his innovative patents and research.
Conclusion
Regis Gayon is a prominent inventor whose work in retroviral systems has the potential to impact gene therapy and biotechnology significantly. His innovative patents reflect his dedication to advancing the field and improving methods for RNA delivery into target cells.